{"id":42051,"date":"2025-12-11T13:00:00","date_gmt":"2025-12-11T13:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4843397_HK43397_0"},"modified":"2025-12-11T13:00:00","modified_gmt":"2025-12-11T13:00:00","slug":"hanchorbio-announces-oral-presentation-of-hcb101-at-the-esmo-immuno-oncology-congress-2025","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=42051","title":{"rendered":"HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025"},"content":{"rendered":"
\n

International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors<\/i><\/p>\n

TAIPEI<\/span>, SHANGHAI<\/span>, AND SAN FRANCISCO<\/span><\/span>, Dec. 11, 2025<\/span><\/span> \/PRNewswire\/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom<\/span>. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its first-ever oral presentation of clinical data at an international oncology congress, following its prior preclinical oral presentation of HCB101 at CSCO 2022.<\/p>\n

\n

\"HanchorBio <\/a>
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025<\/span><\/p>\n<\/p><\/div>\n

The ESMO Immuno-Oncology Congress is Europe’s<\/span> premier meeting dedicated exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.<\/p>\n

Presentation Details:<\/b><\/p>\n

Abstract ID:<\/b> 242MO
Title:<\/b> HCB101, a Differentiated SIRP\u03b1 Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and Lymphoma
<\/i>First Author:<\/b> Dr. Fangling Ning<\/span>, Affiliated Hospital of Binzhou Medical University
Date \/ Time:<\/b> 11 December 2025<\/span> \/ 11:45 \u2013 12:45 GMT<\/span>
Location:<\/b> Whittle Room, Queen Elizabeth II Centre, London<\/span>
Presenter:<\/b> Alvin Luk<\/span>, PhD, MBA, CCRA – President & CMO (Group) and CEO (U.S.A.<\/span>), TIME100 <\/i>Health 2025 Honoree<\/p>\n

“For nearly a decade, CD47 therapies were held back not by flawed biology but by flawed molecules, which struggled to balance safety and efficacy at the same time, especially in immunologically cold tumors,” said Scott Liu<\/span>, PhD, Founder, Chairman, and CEO of HanchorBio<\/b>. “HCB101 was engineered from the ground up to solve that problem. Using AI-guided structural modeling, we identified three core mutations that reshape SIRP\u03b1’s interaction with CD47, allowing us to combine the strengths of first- and second-generation approaches into a single, differentiated molecule. Being selected as one of only 26 mini-oral presentations at ESMO Immuno-Oncology reinforces the field’s recognition of this effort and redefines the CD47 therapies. With its clean safety profile, strong target engagement, and early activity in cold tumors, HCB101 is emerging as a true macrophage-checkpoint backbone \u2013 much like the transformative PD-1\/PD-L1 therapies that were based on T-cell checkpoint inhibition.”<\/p>\n

Key Findings Highlighted in the Mini-Oral<\/u><\/b><\/p>\n

Monotherapy (HCB101-101; NCT05892718)<\/b><\/p>\n